

Key clinical research: Neurologic studies

Assoc. Prof. Noeline Nakasujja, MBChB, M.Med Psych., PhD College of Health Sciences, Makerere University







Aims "Neuro Study"

- To assess neurocognitive co-morbidities and associated depression symptoms in HIV infected individuals.
 - To assess the trajectory of neurocognitive morbidity over two years of follow up on ART
 - To define the level of compartmentalized virus in the CSF and examine associations with dementia, stratified by HIV subtype.



Neurocognitive performance and normative comparison data in HIV+ and HIV- individuals in Rakai, Uganda

HIV+ participants

- ✤ N= 400 HIV positive
- Education 5 yearsAge M 35 years

Matched HIV – 400 Controls





HIV Negative and HIV Positive neurocognitive performance



Neurocognitive performance was lower for HIV positive individuals



HAND: HIV Associated Neurocognitive Disorders

	HIV+ only Cog	only: Pre- and Post-AR Cognitive Function							
	Baseline	Follow-Up	р						
	(n=312)	(n=312)							
Normal	130 (44%)	141 (49%)							
ANI	20 (7%)	39 (13%)							
MND	103 (35%)	97 (33%)	< 0.001						
Dementia	39 (13%)	15 (5%)							

HIV Dementia **BUT** unchanged HAND at 2 years



Baseline Demographic Characteristics by Immunosuppression

	CD4 Category						
	<200 cells/µL (n=150)	350-500 cells/µL (n=183)					
Age, Mean (SD)	33.8 (7.3)	36.8 (9.3)					
Baseline Viral load >1000	148 (98.7%)	163 (89%)					
Men	89 (59.4%)	81 (44.3)					
Women	61 (40.6%)	102 (55.7%)					
Initiated ART	147 (98%)	165 (90%)					

DEPRESSION SYMPTOMS IN HIV POSITIVE INDIVIDUALS AT BASELINE AND 2 YEAR FOLLOW UP



Mean (SD) CES-Depression score was **higher** at baseline 9.6 than at the 2 years 4.4 (7.4) p<0.01



EFFECT OF ART ON DEPRESSION SYMPTOMATOLOGY





HAND and Mortality

	n (%)						
Two-Year Mortality							
Alive	337 (84%)						
Dead	17 (4%)						
LTFU	45 (11%)						

 Each one-stage increase in HAND severity was associated with a 58% increased odds of death at two years [OR 1.58, 95%CI (0.97, 2.57), p=0.06]



Is HIV-1 replication in the CNS associated with neurocognitive impairment?



Baseline log CSF VL (RNA cp/ml) **Compartmentalized:** produced by replication in the CNS



	Subtype					9	Baseline			Follow-up			
	A	с	D	A/C	A/D	Unknown	Median plasma VL (RNA cp/ml)	Median CSF VL (RNA cp/ml)	Median baseline totalZ	Median CD4 count (cells/ul)	Median plasma VL (RNA cp/ml)	Median CSFVL (RNA cp/ml)	Median followup totalZ
Equilibrated (N=18)	5	1	4	1	3	4	6.45E+04	2.29E+04	-0.29	421	Udetectable	Udetectable	0.06
Compartmentalized (N=32)	12	0	10	1	2	7	5.31E+04	4.11E+04	-0.34	454	Udetectable	Udetectable	-0.19

HIV-1 populations in the CSF and plasma were analyzed by deep sequencing with Primer ID in 50 Individuals. Individuals analyzed by sequencing were representative of the overall cohort of HIVinfected people.

> Equilibrated: No evidence of replication in the CNS

64% evidence of CSF HIV compartmentalization affecting verbal learning

Resolving after ART initiation

